The Visceral Adiposity Measurement and Observation Study

Summary

The Visceral Adiposity Measurement and Observation Study

Conditions

• HIV
• HIV-Infections
• HIV-1-infection
• HIV I Infection
• HIV Lipodystrophy
• HIV Infection Primary
• HIV-Associated Lipodystrophy
• HIV Disease Progression
• Lipohypertrophy
• Liver Diseases
• NAFLD
• NASH
• Liver Fibrosis
• Hepatic Fibrosis
• Waist Circumference
• BMI
• Ectopic Fat
• Liver Fat
• Hepatic Steatosis

Interventions

DIAGNOSTIC_TEST

Diagnostic Test

Standard diagnostic tests.

DRUG

HIV Anti-retroviral Background Therapy

All participants are required be on continuous HIV Anti-retroviral Background Therapy. No intervention on drug is part of the Study.

Sponsors & Collaborators

• Dacima Consulting

  collaborator OTHER

• Medpace, Inc.

  collaborator INDUSTRY

• Vanderbilt University Medical Center

  collaborator OTHER

• Echosens

  collaborator INDUSTRY

• Theratechnologies

  lead INDUSTRY

Principal Investigators

• Jordan Lake, MD · The University of Texas Health Science Center, Houston

• John Koethe, MD · Vanderbilt University Medical Center

• Jeffery Carr, DR · Vanderbilt University Medical Center

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-04-18

Primary Completion

2023-10-30

Completion

2023-10-30

Countries

• United States

Study Locations